Sugi Predict

Sugi Predict / Compounds / SCHEMBL4234129

SCHEMBL4234129

SCHEMBL4234129

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(CC)CC)cc4OCC)cc3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 2/20 0.42
▸ MAPT P10636 5/20 0.40
▸ HSD17B10 Q99714 3/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39
▸ CCR3 P51677 1/20 0.39
▸ SSTR5 P35346 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ EGFR P00533 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ HRH3 Q9Y5N1 2/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ PDGFRB P09619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237517 0.96 CCR3 (0.45) MCHR1MAPTHSD17B10HPGDTSHR
SCHEMBL4236062 0.93 MCHR1 (0.47) MCHR1MAPTSMN1; SMN2NPSR1KMT2A
SCHEMBL4233894 0.93 MCHR1 (0.47) MCHR1MAPTSMN1; SMN2NPSR1KMT2A
SCHEMBL4242394 0.93 TAS1R3 (0.43) MCHR1MAPTHSD17B10TSHRSMN1; SMN2
SCHEMBL4229397 0.92 MCHR1 (0.44) MCHR1MAPTSMN1; SMN2NPSR1KMT2A
SCHEMBL4686192 0.92 CCR3 (0.41) MCHR1MAPTHSD17B10HPGDTSHR
SCHEMBL4228669 0.91 HRH3 (0.40) MCHR1MAPTHSD17B10HPGDTSHR
SCHEMBL4234092 0.91 SMN1; SMN2 (0.42) MCHR1MAPTHSD17B10HPGDTSHR
SCHEMBL4238977 0.91 MCHR1 (0.39) MCHR1MAPTHSD17B10HPGDTSHR
SCHEMBL4233740 0.91 MCHR1 (0.39) MCHR1MAPTHSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MCHR1 47/4885MAPT 1398/4885HSD17B10 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.